tbuckley/cabot-search huggingface dataset:
Clinical relevance of internal mammary node drainage in sentinel node biopsy for breast cancer
Authors: A. Goyal, R. G. Newcombe, R. E. Mansel
Journal: Journal of Clinical Oncology (2005)

519 Background: This study was designed to identify the frequency of internal mammary(IM) drainage in patients undergoing sentinel node biopsy(SNB) in a controlled clinical trial. The clinical relevance of internal mammary SNB as a method to improve nodal staging and treatment in breast cancer is investigated. Methods: A total of 1,139 patients with invasive breast cancer underwent SNB based on a standardised protocol using Tc 99m albumin colloid and Patent Blue V injected peritumorally. In 707 patients who participated in the validation phase, SNB was followed by standard axillary treatment in the same operation. Results: Lymphoscintigraphy showed IM sentinel nodes in 106 patients(9%), and IM drainage was identified perioperatively in an additional 14 patients(1%) using the gamma probe. Sampling of the IM basin, was done in 60 of the 120 patients (50%) with IM drainage. Three patients had a pneumothorax and 3 experienced bleeding during IM sampling. IM metastases were detected in 8 of the 60 patients(13%). In 5 patients, IM nodes showed metastatic involvement without accompanying axillary metastases. Four of these patients(7%, 4/60) would have received adjuvant endocrine systemic therapy because of the characteristics of the tumor, but may not have been recommended to receive adjuvant systemic chemotherapy. Therefore, overall a change in management occurred in only 0.7% of patients in our series(7% of the 10% patients with IM node drainage), but 46 patients with unbiopsied “hot” IM nodes remained with unknown internal mammary status. Conclusion: The impact of internal mammary SNB on indication for adjuvant treatment is low and it may be associated with some additional morbidity. Current evidence suggests that internal mammary SNB is still a research tool. No significant financial relationships to disclose.
Genome-wide DNA Methylation Profiling Reveals Methylation Markers Associated with 3q Gain for Detection of Cervical Precancer and Cancer
Authors: Wina Verlaat, Peter J.F. Snijders, Putri W. Novianti, Saskia M. Wilting, Lise M.A. De Strooper, Geert Trooskens, Johan Vandersmissen, Wim Van Criekinge, G. Bea A. Wisman, Chris J.L.M. Meijer, Daniëlle A.M. Heideman, Renske D.M. Steenbergen
Journal: Clinical Cancer Research (2017)

Purpose: Epigenetic host cell changes involved in cervical cancer development following a persistent high-risk human papillomavirus (hrHPV) infection, provide promising markers for the management of hrHPV-positive women. In particular, markers based on DNA methylation of tumor suppressor gene promoters are valuable. These markers ideally identify hrHPV-positive women with precancer (CIN2/3) in need of treatment. Here, we set out to identify biologically relevant methylation markers by genome-wide methylation analysis of both hrHPV-transformed cell lines and cervical tissue specimens.Experimental Design and Results: Genome-wide discovery by next-generation sequencing (NGS) of methyl-binding domain-enriched DNA (MBD-Seq) yielded 20 candidate methylation target genes. Further verification and validation by multiplex-targeted bisulfite NGS and (quantitative) methylation-specific PCR (MSP) resulted in 3 genes (GHSR, SST, and ZIC1) that showed a significant increase in methylation with severity of disease in both tissue specimens and cervical scrapes (P < 0.005). The area under the ROC curve for CIN3 or worse varied between 0.86 and 0.89. Within the group of CIN2/3, methylation levels of all 3 genes increased with duration of lesion existence (P < 0.0005), characterized by duration of preceding hrHPV infection, and were significantly higher in the presence of a 3q gain (P < 0.05) in the corresponding tissue biopsy.Conclusions: By unbiased genome-wide DNA methylation profiling and comprehensive stepwise verification and validation studies using in vitro and patient-derived samples, we identified 3 promising methylation markers (GHSR, SST, and ZIC1) associated with a 3q gain for the detection of cervical (pre)cancer. Clin Cancer Res; 23(14); 3813-22. ©2017 AACR.
External validation of the Glasgow prognostic score (mGPS) for renal cancer.
Authors: Viraj A. Master, Timothy V. Johnson, Omer Kucuk, Daniel Canter, John Pattaras, Ken Ogan, Brian Cross, Peter T Nieh, Wayne Harris
Journal: Journal of Clinical Oncology (2012)

378 Background: Inflammation has been termed the 7 th hallmark of cancer (Hanahan and Weinberg Cell 2011). Measurement of systemic inflammatory responses in malignancy is possible using a selective combination of two commonly available, cost-effective serum assays. The combination of these two serum markers, C-reactive protein (CRP) and albumin, is termed the modified Glasgow prognostic score (mGPS), and is strongly correlated with outcome in a variety of cancers, including mRCC. Recently, mGPS has been shown to be predictive of outcome in localized RCC (ASCO GU 2010 #390). We sought to externally validate these results. Methods: Nephrectomized patients with clinically localized (T1-T4N0M0) clear cell RCC with negative surgical margins were followed for a mean of 25 months (range: 1-81 months). Relapse and survival was identified through routine follow-up. Patients were categorized by mGPS score as Low Risk (mGPS = 0 points), Intermediate Risk (mGPS = 1 point), and High Risk (mGPS = 2 points). One point was assigned to patients for an elevated CRP (&gt;10 mg/L) and hypoalbuminemia (&lt;3.5 mg/dL). Patients with normal CRP and hypoalbuminemia were assigned 0 points. Kaplan-Meier and multivariate Cox regression analyses examined relapse-free survival (RFS) and overall survival (OS) across patient and disease characteristics. Results: Of 248 patients, 17.9% relapsed and 18.6% died. Of Low, Intermediate, and High Risk patients, 7.2%, 7.7%, and 45.5%, respectively relapsed and 5.2%, 15.4%, and 39.4%, respectively died during the study. In multivariate analysis including stage and grade, mGPS was significantly associated with RFS and OS. Compared to Low-Risk patients, High-Risk patients experienced a 3-fold (OR: 2.906, 95% CI: 1.055-8.001) increased risk of relapse and 4-fold (HR: 3.722, 95% CI: 1.046-13.245) increased risk of mortality. AUC is 0.813, which compares very favorably to existing prognostic algorithms. Conclusions: In this external validation cohort of US patients, mGPS continues to be a predictor of relapse and overall mortality following nephrectomy for localized RCC. Clinicians may consider using mGPS as an adjunct to identify high-risk patients for possible enrollment into clinical trials, or for patient counseling.
A phase II trial of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer
Authors: Y. S. Lu, S. H. Kuo, W. P. Su, C. H. Yang, C. Hsu, T. L. Yang, C. S. Huang
Journal: Journal of Clinical Oncology (2005)

861 Background: docetaxel (T), capecitabine (X), and cisplatin (P) are active chemotherapy for patients (pts) with breast carcinoma. Synergistic cytotoxicity of these drugs has been demonstrated in vitro. This study sought to determine the efficacy of combining these three drugs in the treatment of chemotherapy- naïve pts with locally advanced breast carcinoma (LABC). Methods: Pts with histologically proven, chemotherapy-naïve LABC (AJCC stage IIIa or IIIb) were eligible. The regimen consisted of 4 cycles of T 60 mg/m2 intravenously by 1-hour infusion immediately followed by P 50 mg/m2 intravenously by 24-hour infusion on day 1, and X 1800 mg/m2/day p.o. day1 to day 14, repeated every 3 weeks. Results: 30 pts were enrolled into this study. Pts and tumor characteristics were (median(range)): age 49 years (35–66); tumor size: 8.0 cm (5.5–15); N+: 20 pts; hormone receptor positive/negative: 21/9 pts; Her2/neu <3+/3+: 23/7 pts. A total of 116 cycles were administered. No prophylactic G-CSF was used. The predominant toxicity was grade 3/4 neutropenia encountered in 11%/13% of 116 cycles. Febrile neutropenia occurred in 1.7%, grade 2 anemia in 3.4% of cycles, respectively. There are no grade 3/4 non-hematological toxicities. Common grade 1/2 non-hematological toxicities were nausea (67%), vomiting (27%), diarrhea (7%), mucositis (13%), nail changes (12%), and hand-foot syndrome (20%). At this time, 28 pts were evaluable for clinical response. There were 7 clinical complete response (CR) and 21 partial responses (PR), for an overall response rate of 100%. Pathological response has been evaluated in 24 pts, of which 5 achieved a pathological CR (21%). Accrual is ongoing. Conclusions: preliminary results indicate that triplet TXP can be safely administered and is highly active as neoadjuvant chemotherapy with substantial clinical and pathological response rates in pts with LABC. Update results will be presented at the meeting. No significant financial relationships to disclose.
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial
Authors: L Rosiñol, A Oriol, A I Teruel, A L de la Guía, MaJ Blanchard, J de la Rubia, M Granell, MaA Sampol, L Palomera, Y González, MaA Etxebeste, R Martínez-Martínez, M T Hernández, F de Arriba, A Alegre, MaT Cibeira, MaV Mateos, J Martínez-López, J J Lahuerta, J San Miguel, J Bladé
Journal: Leukemia (2017)
Immunostimulatory CpG Oligodeoxynucleotides Induce Sustained ERK2 Activation and Strong Proliferative Responses in CLL B-Cells from Patients with Progressive Disease.
Authors: Aleksandar Petlickovski, Luca Laurenti, Stefania Gobessi, Simona Sica, Giuseppe Leone, Dimitar, G. Efremov
Journal: Blood (2005)
Fibrosis evaluation by transient elastography in alcoholic liver disease: Is the histological scoring system impacting cutoff values?
Authors: Carolin Lackner, Ramon Bataller, Alastair Burt, Rosa Miquel, Detlef Schuppan, Dina Tiniakos, Michael Trauner
Journal: Hepatology (2017)

Lackner, Carolin M.D.; Bataller, Ramon M.D., Ph.D.; Burt, Alastair B.Sc. (Hons.), M.D.; Miquel, Rosa M.D., Ph.D.; Schuppan, Detlef M.D., Ph.D.; Tiniakos, Dina M.D., Ph.D., F.R.C.Path.; Trauner, Michael M.D. Author Information
Epidemiology, survival, incidence and prevalence of idiopathic pulmonary fibrosis in the USA and Canada
Authors: Sergio Harari, Antonella Caminati, Fabiana Madotto, Sara Conti, Giancarlo Cesana
Journal: European Respiratory Journal (2017)

It was interesting to read the paper by Raghu et al. [1] in the July issue of the European Respiratory Journal ( ERJ ). The article evaluated the epidemiology of idiopathic pulmonary fibrosis (IPF) in 18–64 year-olds in the USA. Epidemiological studies in IPF: pitfalls in methodologies and data interpretation <http://ow.ly/QE1K302X9Bz>
B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia
Authors: Francesco Maura, Carlo Visco, Erika Falisi, Reda Gianluigi, Sonia Fabris, Luca Agnelli, Giacomo Tuana, Marta Lionetti, Nicola Guercini, Elisabetta Novella, Ilaria Nichele, Anna Montaldi, Francesco Autore, Anna Ines Gregorini, Wilma Barcellini, Vincenzo Callea, Francesca Romana Mauro, Luca Laurenti, Robin Foa, Antonino Neri, Francesco Rodeghiero, Agostino Cortelezzi
Journal: Blood (2012)
The microRNA-423-3p-Bim Axis Promotes Cancer Progression and Activates Oncogenic Autophagy in Gastric Cancer
Authors: Pengfei Kong, Xiaofeng Zhu, Qirong Geng, Liangping Xia, Xiaowei Sun, Yingbo Chen, Wei Li, Zhiwei Zhou, Youqing Zhan, Dazhi Xu
Journal: Molecular Therapy (2017)

Human serum microRNAs (miRNAs) have been shown to serve as disease fingerprints for predicting survival of cancer patients. However, the roles of specific miRNAs involved in gastric cancer (GC) are largely unknown. In this study, miRNA profiling was performed on sera obtained from six patients in good- and poor-survival groups. Expression of miR-423-3p was validated by quantitative RT-PCR in another 67 GC serum samples and paired normal and cancerous gastric tissues. Luciferase reporter assays were used to identify the target gene Bcl-2-interacting mediator of cell death (Bim). As a result, between the good-survival and poor-survival groups, the expression of nine serum miRNAs was altered more than two-fold. Among these, miR-423-3p was significantly increased in the poor-survival group, and its overexpression in GC tissues predicted poor survival in 119 patients with GC. miR-423-3p was found to promote cell proliferation, migration, and invasion in cell lines and animal models. Mechanistically, knockdown of the autophagy-related gene (Atg) 7 rescued the GC-promoting effect of miR-423-3p. In conclusion, miR-423-3p activates oncogenic and Beclin-1-dependent autophagy and promotes GC progression by reducing the expression of Bim. The newly identified miR-423-3p-Bim axis might be a potential therapeutic target in GC. Human serum microRNAs (miRNAs) have been shown to serve as disease fingerprints for predicting survival of cancer patients. However, the roles of specific miRNAs involved in gastric cancer (GC) are largely unknown. In this study, miRNA profiling was performed on sera obtained from six patients in good- and poor-survival groups. Expression of miR-423-3p was validated by quantitative RT-PCR in another 67 GC serum samples and paired normal and cancerous gastric tissues. Luciferase reporter assays were used to identify the target gene Bcl-2-interacting mediator of cell death (Bim). As a result, between the good-survival and poor-survival groups, the expression of nine serum miRNAs was altered more than two-fold. Among these, miR-423-3p was significantly increased in the poor-survival group, and its overexpression in GC tissues predicted poor survival in 119 patients with GC. miR-423-3p was found to promote cell proliferation, migration, and invasion in cell lines and animal models. Mechanistically, knockdown of the autophagy-related gene (Atg) 7 rescued the GC-promoting effect of miR-423-3p. In conclusion, miR-423-3p activates oncogenic and Beclin-1-dependent autophagy and promotes GC progression by reducing the expression of Bim. The newly identified miR-423-3p-Bim axis might be a potential therapeutic target in GC.
Pre-Transplant 5-Azacitidine (Vidaza®) May Improve Outcome of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Myelodysplastic Syndrome (MDS).
Authors: Teresa Field, Janelle Perkins, Melissa Alsina, Ernesto Ayala, Hugo F. Fernandez, William Janssen, Mohamed Kharfan-Dabaja, Jeffery Lancet, Lia Perez, Daniel Sullivan, Alan List, Claudio Anasetti
Journal: Blood (2006)
Effect of PDMP, a Glucosylceramide Synthase Inhibitor, On Resistance to Daunorubicin in Human Leukemia Cell Line K562/A02.
Authors: Bao-An Chen, Li Yin, Jian Cheng, Jia-hua Ding, Chong Gao, Gang Zhao, Jun Wang, Guo-hua Xia, Ning-Na Chen, Xiao-Ping Pei
Journal: Blood (2009)
Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch Cutaneous Lymphoma Group
Authors: S. van Santen, R. van Doorn, K.J. Neelis, L.A. Daniëls, B. Horváth, M.S. Bruijn, C.J.G. Sanders, M.M. van Rossum, E.R.M. de Haas, J.C.J.M. Veraart, M.W. Bekkenk, M.H. Vermeer, R. Willemze
Journal: British Journal of Dermatology (2017)

Folliculotropic mycosis fungoides (FMF) is an aggressive variant of mycosis fungoides (MF) and generally less responsive to standard skin‐directed therapies (SDTs). Recent studies distinguished indolent (early‐stage FMF) and more aggressive (advanced‐stage FMF) subgroups. The optimal treatment for both subgroups remains to be defined. To evaluate initial treatment results in patients with early‐ and advanced‐stage FMF. A study was undertaken of 203 patients (84 early‐stage, 102 advanced‐stage, 17 extracutaneous FMF) included in the Dutch Cutaneous Lymphoma Registry between 1985 and 2014. Type and results of initial treatment were retrieved from the Dutch Registry. Main outcomes were complete remission (CR); sustained complete remission; partial remission (PR), > 50% improvement; and overall response (OR; CR + PR). Patients with early‐stage FMF were treated with nonaggressive SDTs in 67 of 84 cases resulting, respectively, in CR and OR of 28% and 83% for monotherapy topical steroids, 0% and 83% for ultraviolet B (UVB), and 30% and 88% for psoralen plus ultraviolet A (PUVA). In patients with advanced‐stage FMF these SDTs were less effective (combined CR and OR 10% and 52%, respectively). In patients with advanced‐stage FMF local radiotherapy (CR 63%; OR 100%), total skin electron beam irradiation (CR 59%; OR 100%) and PUVA combined with local radiotherapy (CR 5%, OR 75%) were most effective. The results of the present study demonstrate that not all patients with FMF should be treated aggressively. Patients with early‐stage FMF may benefit very well from standard SDTs also used in early‐stage classic MF and have an excellent prognosis.
Prognostic Implication of Therapy-Related Acute Myeloid Leukemia after Comparative Analysis with De Novo acute Myeloid Leukemia
Authors: Jae-Ho Yoon, Byung-Sik Cho, Hee-Je Kim, Seung-Ah Yahng, Seung-Hwan Shin, Sung-Eun Lee, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min
Journal: Blood (2015)
Renal biopsies should be performed whenever treatment strategies depend on renal involvement
Authors: Gillian Divard, Aurelie Sannier, Guillaume Hanouna, Eric Daugas, Francois Vrtovsnik, Jonathan M Chemouny
Journal: Annals of the Rheumatic Diseases (2017)

We read with great interest the European League Against Rheumatism/European Renal Association–European Dialysis and Transplant Association guidelines for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).1 We strongly support the recommendation of performing a renal biopsy whenever a renal involvement is suspected as the only organ-threatening or life-threatening manifestation. Indeed, we came across several cases of different diseases presenting as AAV which support this recommendation, as exemplified below. An 18-year-old woman self-presented to the emergency department (ED) with abdominal pain, diarrhoea, gross …
IPH1101, the First Specific γδ T Cell Agonist, Shows Potent Immuno-Biological Efficacy in Low Grade Follicular Lymphoma Patients When Combined with Rituximab: Results From a Phase II Study.
Authors: Claire Lucas, Sophie Ingoure, Elodie Soule, Bruna Faria, Fabien Audibert, Mathieu Blery, Lucile Beautier, Francois Romagne, Sylvie de Micheaux, Helene Sicard
Journal: Blood (2009)
Expansion of Polyclonal CD4+CD25high Foxp3+ Regulatory T-Cells in High Risk Myelodysplastic Syndromes (MDS).
Authors: Shahram Y. Kordasti, Wendy Ingram, Janet Hayden, David Darling, Linda Barber, Farzin Farzaneh, Ghulam J. Mufti
Journal: Blood (2006)
Susceptibility towards Irradiation-Induced Bone Marrow (BM) Dysplasia in Vivo Is Determined by the BM Vasculogenic Phenotype: Correlation with MDS Patients BM Samples
Authors: Catarina Osorio, Catia Igreja, Rita Fragoso, Manuela Ferreira, Tania Carvalho, Andreia Mendonca, Maria Gomes Silva, Sergio Dias
Journal: Blood (2008)
C57BL/6JOlaHsd Mice with Tandem Deletion of the Multimerin 1 and Alpha-Synuclein Genes Have Impaired Platelet Function in Vivo and in Vitro That Can Be Corrected by Multimerin 1
Authors: Subia Tasneem, Adili Reheman, Heyu Ni, Catherine P.M. Hayward
Journal: Blood (2008)
Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men
Authors: Jasmine J. Han, Thomas H. Beltran, John W. Song, John Klaric, Y. Sammy Choi
Journal: JAMA Oncology (2017)

Human papillomavirus (HPV) is a common sexually transmitted infection that is a major cause of noncervical anogenital and oropharyngeal cancers. Prophylactic HPV vaccine is available for primary prevention. However, the population prevalence data for male genital HPV infection is not well known, while the HPV vaccination coverage is low in the United States.To estimate the prevalence of genital HPV infection and the HPV vaccination rate in the United States among adult men and to examine potential risk factors for HPV infection.The National Health and Nutrition Examination Survey (NHANES) samples a representative cross-section of the US population. Men aged 18 to 59 years were examined in mobile examination centers during the NHANES 2013-2014. DNA was extracted from self-collected penile swab specimens, and HPV genotyping was performed by polymerase chain reaction amplification. Demographic and vaccination information was gathered via self-report during home-based standardized interviews. Binary multivariable logistic regression was used to estimate the odds of HPV infection.The prevalence of genital HPV infection and the HPV vaccination coverage rate among adult men.During the NHANES 2013-2014, a total of 1868 men aged 18 to 59 years were examined. The overall genital HPV infection prevalence was 45.2% (95% CI, 41.3%-49.3%). The infection prevalence with at least 1 high-risk HPV subtype defined by DNA testing was 25.1% (95% CI, 23.0%-27.3%). In vaccine-eligible men, the prevalence of infection with at least 1 HPV strain targeted by the HPV 4-valent vaccine and HPV 9-valent vaccine was 7.1% (95% CI, 5.1%-9.5%) and 15.4% (95% CI, 11.7%-19.6%), respectively. Among vaccine-eligible men, the HPV vaccination coverage was 10.7% (95% CI, 7.8%-14.6%).Among men aged 18 to 59 years in the United States, the overall prevalence of genital HPV infection was 45.2% (95% CI, 41.3%-49.3%). The overall genital HPV infection prevalence appears to be widespread among all age groups of men, and the HPV vaccination coverage is low.
Orthopaedic trainees launch anti-bullying programme
Authors: Abi Rimmer
Journal: BMJ (2017)

A programme to tackle a culture of bullying, undermining behaviour, and harassment in trauma and orthopaedic surgery has been launched by the British Orthopaedic Trainees Association and the British Orthopaedic Association.

The #HammeritOut initiative, launched earlier this month (www.bota.org.uk/hammer-it-out), is supported by several organisations, including the Academy of Medical Royal Colleges and the Royal College of Surgeons. The initiative aims to create a “positive workplace culture” in trauma and orthopaedics.

Simon Fleming, president of the British Orthopaedic Trainees Association, said that the …
Do Erythropoiesis-Stimulating Agents (ESAs) Affect Survival in Anemic Patients with Myelodysplastic Syndromes (MDS)?
Authors: Amy J. Davidoff, Xuehua Ke, Maria R. Baer, Sheila R Weiss Smith, Dan Zandberg, Franklin Hendrick, Masayo Sato, Peter L. Greenberg, Steven D. Gore
Journal: Blood (2011)